Agile Therapeutics, Inc. filed its 10-K on Mar 23, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.376 USD | +0.13% | -9.33% | -80.72% |
Mar. 28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M | MT |
1st Jan change | Capi. | |
---|---|---|
-80.72% | 2.57M | |
+5.01% | 109B | |
+11.53% | 105B | |
+0.23% | 22.25B | |
-12.22% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.05% | 16.85B | |
+4.71% | 13.76B | |
+34.95% | 12.46B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt